Odonate, Inc.

Equities

ODTC

US6760792050

Pharmaceuticals

Market Closed - OTC Markets 01:51:38 2024-03-28 pm EDT 5-day change 1st Jan Change
3,500 USD +3.24% Intraday chart for Odonate, Inc. +4.48% +16.67%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
North American Morning Briefing : Recession Threat Grows as Further Tightening Likely DJ
North American Morning Briefing : Stock Futures -2- DJ
North American Morning Briefing : Caution Ahead of Fed, Inflation Data to Hold Back Stocks DJ
North American Morning Briefing : Stock Futures -2- DJ
North American Morning Briefing : Investors Await -2- DJ
North American Morning Briefing : Powell on Tap -2- DJ
North American Morning Briefing : Hopes of Easing -2- DJ
North American Morning Briefing : Caution -2- DJ
North American Morning Briefing : Stock Futures -2- DJ
North American Morning Briefing : Tech Futures -2- DJ
North American Morning Briefing : Stocks Waver, -3- DJ
North American Morning Briefing : Stocks to Open -3- DJ
Odonate Therapeutics, Inc.(NasdaqGS:ODT) dropped from S&P Global BMI Index CI
Odonate Therapeutics, Inc.(NasdaqGS:ODT) dropped from S&P TMI Index CI
Odonate Therapeutics, Inc.(NasdaqGS:ODT) dropped from NASDAQ Composite Index CI
Top Midday Decliners MT
Odonate Therapeutics Gets Nasdaq Notice to Delist Shares MT
Odonate Therapeutics, Inc.(NasdaqGS:ODT) dropped from NASDAQ Biotechnology Index CI
Insider Sell: Odonate Therapeutics MT
Odonate Therapeutics Plans Share Buybacks After Halting Development of Breast Cancer Drug MT
Odonate Therapeutics, Inc. announces an Equity Buyback for 20,000,000 shares, representing 51.95% of its issued share capital. CI
Odonate Therapeutics, Inc. authorizes a Buyback Plan. CI
Odonate Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
North American Morning Briefing : Stock Futures -3- DJ
Odonate Therapeutics, Inc. Announces Termination of Joseph O’Connell as Chief Medical Officer CI
Chart Odonate, Inc.
More charts
Odonate, Inc., formerly Odonate Therapeutics, Inc., is a pharmaceutical company. The Company is focused on the development of tesetaxel, an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are used in the treatment of cancer. The Company is no longer in development of tesetax.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
  1. Stock
  2. Equities
  3. Stock Odonate, Inc. - OTC Markets
  4. News Odonate, Inc.
  5. Odonate Therapeutics : Discloses 'Positive' Phase 3 Trial Results for Metastatic Breast Cancer